Clinical trials: Oral
Diabetic Gastroparesis
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
To determine whether a new Orally Disintegrating Tablet of Reglan (metoclopramide) is metabolized faster than the conventional Reglan tablet in patients with diabetic gastroparesis, pharmacokinetics following a single 10 mg dose…
- Trial name
- NCT00139893
- Testing
- Reglan ODT
- Where
- United States
- Sponsor
- UCB Pharma
Diabetes Mellitus, Type 2
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)
To investigate the glycosylated hemoglobin (HbA1c) control of Glimepiride (AMARYL) as OAD initiation mono-therapy in type 2 diabetic patients in China.
- Trial name
- GREAT (NCT00908921)
- Testing
- GLIMEPIRIDE
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Sanofi
Facial Palsy, Stroke Rehabilitation
Facial Palsy Treatment
The Primary objective of the study is to investigate the most effective treatment modalities available to speech language pathologist as well as movement difference by comparing them.
- Trial name
- NMES (NCT06976814)
- Testing
- Neuro muscular electrical stimulation, Beckmann's oral motor exercises
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
Follicle Development, Ovarian Follicle
A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives
This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in…
- Conditions
- Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size
- Trial name
- NCT01291004
- Testing
- Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive
- Where
- 2 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Healthy
Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a daily oral dose of LHF-535 administered for 14 days to healthy participants.
- Trial name
- NCT03993704
- Testing
- LHF-535
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kineta Inc.
Peanut Allergy
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
- Trial name
- NCT03292484
- Testing
- AR101
- Where
- 93 sites in United States, Canada and 8 more
- Volunteers
- 911 people
- Sponsor
- Aimmune Therapeutics, Inc.
Healthy Participants
A Study of Experimental Medication BMS-986278 Given to Healthy Participants
The purpose of this study is to investigate experimental medication BMS-986278 given to healthy participants.
- Trial name
- NCT03429933
- Testing
- BMS-986278
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy, Asthma
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects
To investigate safety, tolerability, pharmacokinetics including posology, and pharmacodynamics of multiple rising doses of BI 1021958 in otherwise healthy mild asthmatic subjects
- Trial name
- NCT01629849
- Testing
- BI 1021958 bid, BI 1021958 qd
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC [2.5/ 5µg and 5/ 5µg] delivered by the RESPIMAT with the lung function profile of twice daily treatment…
- Trial name
- NCT01969721
- Testing
- fluticasone propionate, salmeterol, tiotropium
- Where
- 29 sites in Belgium, Czechia and 6 more
- Volunteers
- 229 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT00559533
- Testing
- RO5045337
- Where
- 7 sites in United States, France
- Volunteers
- 106 people
- Sponsor
- Hoffmann-La Roche
Gout
Efficacy and Safety of Oral Febuxostat in Participants With Gout
The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
- Trial name
- CONFIRMS (NCT00430248)
- Testing
- Febuxostat, Allopurinol
- Where
- 258 sites in United States
- Volunteers
- 2,269 people
- Sponsor
- Takeda
Anaemia
Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers
This study is being performed to comply with regulatory requirements that all new non-antiarrhythmic drugs must be assessed for potential effects on cardiac repolarization through electrocardiographic evaluation in a 'Thorough…
- Trial name
- NCT02293148
- Testing
- GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Microbiome, Cytokines
Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis
This study is a six-week, double-blind, randomized, parallel-group controlled clinical study. The objective of this study is to evaluate the changes to the oral microbiome, inflammatory mediators, gingival health indices and to…
- Conditions
- Microbiome, Cytokines, Plaque, Gingivitis
- Trial name
- NCT07501455
- Testing
- Distilled Water, Marketed Comparator 1, Marketed Comparator 2
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Kenvue Brands LLC
Healthy Participants
A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults
ASP8731 is a potential new treatment for people with sickle cell disease. Before ASP8731 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body.
- Trial name
- NCT05167526
- Testing
- ASP8731
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor…
- Trial name
- NCT04505826
- Testing
- OP-1250
- Where
- 19 sites in United States, Australia
- Volunteers
- 153 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Healthy Volunteer
A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants
This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.
- Trial name
- 528 Asian PK (NCT06722417)
- Testing
- Icalcaprant
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Participants
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
The purpose of this study is to evaluate the drug interaction between povorcitinib and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
- Trial name
- NCT06380205
- Testing
- Povorcitinib, Levonorgestrel/Ethinyl estradiol
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Lymphoma, Cancer
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
- Conditions
- Lymphoma, Cancer, Thyroid Carcinoma
- Trial name
- NCT00215605
- Testing
- XL184
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Exelixis
Healthy
Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects
This study will evaluate the effect of 600 mg daily oral dose of rifampin (CYP3A4 inducer) on the pharmacokinetics of a single 400 mg oral dose of nilotinib in healthy subjects
- Trial name
- NCT00418756
- Testing
- Nilotinib
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy
Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers
To investigate the bioavailability of dabigatran with and without concomitant administration of atorvastatin and the bioavailability of atorvastatin with and without concomitant administration of dabigatran etexilate
- Trial name
- NCT02171039
- Testing
- Dabigatran, Atorvastatin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim